ESSA Shareholders Give Green Light to XenoTherapeutics Acquisition
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 06 2025
0mins
Source: Newsfilter
Acquisition Approval: ESSA Pharma Inc. has received overwhelming approval from its Securityholders for the acquisition by XenoTherapeutics Inc., with over 99% of votes in favor during a special meeting.
Next Steps: The transaction is pending approval from the Supreme Court of British Columbia, with a court hearing scheduled for October 7, 2025, and completion expected around October 9, 2025.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
